165 related articles for article (PubMed ID: 23229855)
1. Interspecies modeling and prediction of human exenatide pharmacokinetics.
Chen T; Mager DE; Kagan L
Pharm Res; 2013 Mar; 30(3):751-60. PubMed ID: 23229855
[TBL] [Abstract][Full Text] [Related]
2. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
Gao W; Jusko WJ
Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
Chen T; Kagan L; Mager DE
J Pharm Sci; 2013 Oct; 102(10):3844-51. PubMed ID: 23897494
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.
Li X; Zhao Z; Li L; Zhou T; Lu W
Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
Cirincione B; Edwards J; Mager DE
AAPS J; 2017 Mar; 19(2):487-496. PubMed ID: 27896683
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
[TBL] [Abstract][Full Text] [Related]
11. Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion.
Cirincione B; LaCreta F; Sager P; Mager DE
J Clin Pharmacol; 2017 Aug; 57(8):956-965. PubMed ID: 28543393
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of exenatide.
Cirincione B; Mager DE
Br J Clin Pharmacol; 2017 Mar; 83(3):517-526. PubMed ID: 27650681
[TBL] [Abstract][Full Text] [Related]
13. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
Kim D; Jeon H; Ahn S; Choi WI; Kim S; Jon S
J Control Release; 2017 Jun; 256():114-120. PubMed ID: 28457895
[TBL] [Abstract][Full Text] [Related]
14. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.
Kagan L; Abraham AK; Harrold JM; Mager DE
Pharm Res; 2010 May; 27(5):920-32. PubMed ID: 20232116
[TBL] [Abstract][Full Text] [Related]
15. Rapidly dissolvable microneedle patches for transdermal delivery of exenatide.
Zhu Z; Luo H; Lu W; Luan H; Wu Y; Luo J; Wang Y; Pi J; Lim CY; Wang H
Pharm Res; 2014 Dec; 31(12):3348-60. PubMed ID: 24867426
[TBL] [Abstract][Full Text] [Related]
16. The use of low molecular weight protamine to enhance oral absorption of exenatide.
Zhang L; Shi Y; Song Y; Sun X; Zhang X; Sun K; Li Y
Int J Pharm; 2018 Aug; 547(1-2):265-273. PubMed ID: 29800739
[TBL] [Abstract][Full Text] [Related]
17. The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
Li X; Wang C; Liang R; Sun F; Shi Y; Wang A; Liu W; Sun K; Li Y
Pharm Res; 2015 Mar; 32(3):1017-27. PubMed ID: 25270570
[TBL] [Abstract][Full Text] [Related]
18. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats.
Kwak HH; Shim WS; Hwang S; Son MK; Kim YJ; Kim TH; Yoon ZH; Youn HJ; Lee GI; Kang SH; Shim CK
Pharm Res; 2009 Nov; 26(11):2504-12. PubMed ID: 19756973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
